Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma
Evan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, Evan Seffar, Mark A Dickson, Viswatej Avutu, Lauren B Banks, Jason E Chan, Ping Chi, Mrinal M Gounder, Ciara M Kelly, Mary L Keohan, Robert G Maki, Sujana Movva, Damon Reed, Rhoena Desir, Matthew Biniakewitz, Jae-Mun Cho, Michele Duchemin, Josep · 2026
Read Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma by Evan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, Evan Seffar, Mark A Dickson, Viswatej Avutu, Lauren B Banks, Jason E Chan, Ping Chi, Mrinal M Gounder, Ciara M Kelly, Mary L Keohan, Robert G Maki, Sujana Movva, Damon Reed, Rhoena Desir, Matthew Biniakewitz, Jae-Mun Cho, Michele Duchemin, Josep (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13141240.txt.
Description
A large team at Memorial Sloan Kettering reports a phase 2 trial in a rare fat cancer in 2026. The cancer, called DDLPS, often stops growing for a time on a drug that blocks two cell-cycle enzymes. Most tumors start growing again, though, and lab work hints the blocker may also stir up immune cells inside tumors. The trial paired the blocker, palbociclib, with an immune drug, retifanlimab, in 30 patients with advanced disease.
Two in ten patients saw their tumors shrink, and just over half got some lasting benefit. Half the group stayed free of growth for about five months, and half lived about 27 months. Most patients had never had drug treatment before this trial. The authors read the results as a sign that pairing the two drugs is worth testing further in this hard-to-treat cancer.
Catalog record
| CREATOR | Evan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, Evan Seffar, Mark A Dickson, Viswatej Avutu, Lauren B Banks, Jason E Chan, Ping Chi, Mrinal M Gounder, Ciara M Kelly, Mary L Keohan, Robert G Maki, Sujana Movva, Damon Reed, Rhoena Desir, Matthew Biniakewitz, Jae-Mun Cho, Michele Duchemin, Josep |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |